X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: New product introduction... - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Aug 28, 2007

    Pharma: New product introduction...

    The introduction of the product patent law has led the Indian pharma companies to adopt a host of strategies to augment their revenue streams and sustain the pace of new product launches especially in the domestic market. It is expected that while there is not likely to be any significant impact in the medium term, in the long term, the number of new product launches especially from domestic pharma companies are expected to slow down as they can no longer bank on reverse engineering of drugs. At the same time MNC pharma companies are expected to accelerate the pace of new product launches from their parent's folio. In this article, we shall take a look at the strategies being adopted by companies to launch new products in the domestic market.

    New chemical entity (NCE): Though no significant benefits will accrue from new drug discovery research in the short term, from a long-term perspective, if a drug is successful, then the potential upside in terms of revenues and profitability is huge. No major domestic company focused on R&D from 1970 till the early 90s due to the process patent law prevalent in India. However, in anticipation of the product patent law 2005 onwards, domestic pharma companies such as Ranbaxy, Dr.Reddy's, Glenmark Pharma, Biocon and Wockhardt began focusing on building an R&D programme from the mid 90s.

    However, the programmes of these companies are still in the nascent stages in comparison to their global counterparts. The riskiness for domestic companies is also higher, as they have only four to five molecules in the pre-clinical stages, which is considerably lesser than their global peers. Having said that, last month, Dr.Reddy's anti-diabetic molecule 'Balaglitazone' reached the Phase III clinical trials and is the first drug from any domestic pharma company to reach this stage.

    In-licensing of drugs: Given the fact that most of the domestic pharma companies have started their R&D programme, it will be a while before an NCE gets launched commercially in the market. In fact, the earliest possible launch date is not expected to be before 2009/2010. In the meanwhile, to keep up the pace of growth, Indian pharma companies are looking to adopt the in-licensing route to launch new products. Alliances are generally struck with global innovator companies, who do not have a strong presence in the Indian market. These companies, rather than building a presence from scratch, are partnering with Indian companies, as the latter have strong marketing and distribution networks in place in India. Thus, global companies are looking to leverage the same to increase the reach and consequently, revenues from its products. This is a beneficial arrangement for Indian companies too, as they can have a share in the revenues generated from these in-licensed products and further strengthen their presence in the domestic market.

    Launching from parent's folio: With the introduction of the product patent law, product launches by MNC pharma from their respective parent's folio is set to accelerate. While certain pre-1995 patented products have been launched in the Indian markets, post-1995 patented launches will most likely take place after 2007. Therefore post 2007, the value of the Indian pharma market is expected to be significantly higher than the market value at present.

    That said, pricing of these drugs will be the key factor to watch out for going forward. It must be noted that the government is likely to subject patented drugs of MNCs to price negotiation, while those of the domestic companies could be exempted. The rationale behind this move seems to be the fact that for MNC companies, India is just one of their many global markets to recoup R&D costs, while domestic companies are likely to receive differential treatment to promote indigenous research.

    To sum up...
    We believe that with the ushering of the patent law in the country, companies investing in R&D will stand to benefit in the long-term despite the risks involved. Considering that Indian companies do not have the resources and the money required to invest in the entire stage of development of the molecules, we remain positive on the partnership strategies followed by these companies. Similarly, in-licensing of molecules will also enable both domestic and MNC companies to keep up the pace of new product launches going forward.

     

     

    Equitymaster requests your view! Post a comment on "Pharma: New product introduction...". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE HEALTHCARE


    Aug 18, 2017 (Close)

    S&P BSE HEALTHCARE 5-YR ANALYSIS

    COMPARE COMPANY

    MARKET STATS